EHA Grants Hall of Fame

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Current status of the Clinical Trials Regulation

HemAffairs Article #2 – June 2019

In 2014 the European Parliament approved the Clinical Trials Regulation (CTR) that is supposed to replace the Clinical Trials Directive (CTD) from 2001. Five years later, the regulation has not yet become applicable.

Position of EHA on Access to Medicines

 

There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.

Highlights of Past EHA (HOPE) Asia 2020

October 16-17 2020
Meeting Chairs:

Dr N Senadheera (Sri Lanka College of Haematologists)
Prof J Gribben (European Hematology Association)

This second edition of HOPE Asia was presented together with the Sri Lanka College of Haematologists (SLCH) on October 16 and 17, 2020.…

Statement of Solidarity after Earthquake in Morocco

On behalf of the European Hematology Association, I would like to express my deepest condolences and heartfelt support to the people of Morocco who have been affected by the recent earthquake.

Highlights of Past EHA (HOPE) EMEA 2020

Highlights of Past EHA (HOPE) EMEA 2020
October 9-10, 2020
Meeting Chairs:

Prof J Gribben (European Hematology Association)
Prof GH Özsan

In the second weekend of October, EHA and the Turkish Society of Hematology (TSH) kicked-off the very first virtual HOPE meeting.…